1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. CENTURY THERAPEUTICS INC
Century Therapeutics Inc
XNAS: IPSC
1.48-0.05(-3.27%)
771.3K
XNAS Volume

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Century Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Century Therapeutics Inc share price target, revenues, EPS, net income and more

Century Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • NEUTRAL

    Quarterly Revenue Century Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Century Therapeutics Inc Jun-2026 Quarterly Net Profit is $-35 Million which is growth of -6.2% YoY.

Century Therapeutics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
109.24.20.80.80.90.30.20.1
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
25.423.720.729.434.73537.135.635.532.230.931.831
Operating Profit
-25.4-23.7-20.7-29.4-34.774.2-33-34.8-34.8-31.3-30.6-31.6-30.9
221.31.622.42.93.33.63.23.53.52.9
Profit Before Tax
-34.6-21.6-19.2-34.4-32.576.6-34.3-31.2-31.2-28.1-40.3-32.1-32.3
Tax
---0.11.8-00-0.90.61
⌄
-34.6-21.6-19.2-34.4-32.576.6-36.1-31.2-31.2-28.1-39.4-32.7-33.3
Diluted NI Avail to Com Stockholders Ann.
-34.6-21.6-19.2-34.4-32.576.6-36.1-31.2-31.2-28.1-39.4-32.7-33.3
Basic EPS
-0.2-0.1-0.3-0.4-0.40.9-0.4-0.4-0.4-0.5-0.7-0.6-0.6
Diluted EPS After ExtraOrdinary
-0.1-0.1-0.3-0.3-0.40.9-0.4-0.4-0.4-0.5-0.4-0.5-0.5
Number Of Shares End
205.8193.587.386.586.28685.484.782.162.36059.559.3
Net Income Continuing Discontinued Operations
-34.6-21.6-19.2-34.4-32.576.6-36.1-31.2-31.2-28.1-39.4-32.7-33.3
Normalized Income
-23.4-21.6-19.2-27.7-32.576.6-32.7-31.2-31.2-28.1-26.5-29.6-30
Interest Income
221.31.622.42.93.33.63.23.53.53.1
Interest
------0.1
Net Interest Income
221.31.622.42.93.33.63.23.53.52.9
EBIT
-25.4-23.7-20.7-29.4-34.774.2-34.3-31.2-31.2-28.1-40.3-32.1-32.2
EBITDA
-22.8-20.7-17.1-26.2-31.577.4-31-27.9-27.7-24.8-36.7-28.8-29
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
2.633.63.13.23.23.33.33.53.23.63.43.2
Profit From Continuing Operations
-34.6-21.6-19.2-34.4-32.576.6-36.1-31.2-31.2-28.1-39.4-32.7-33.3
Normalized EBITDA
-11.6-20.7-17.1-19.5-31.577.4-26.7-27.9-27.7-24.8-23.6-24.8-24.8
*All financials are in USD Million and price data in USD

Century Therapeutics Inc competitor comparison and performance snapshot within industry

Century Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • POSITIVE

    Annual Revenue Century Therapeutics Inc Dec-2025 Annual Revenue is $109 Million which is growth of 1556.8% YoY.

  • POSITIVE

    Annual Net Profit Century Therapeutics Inc Dec-2025 Annual Net Profit is $-10 Million which is growth of 92.4% YoY.

Century Therapeutics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
175.9%
-
 109.26.62.25.2
Cost Of Rev. Ann.
-
-
 -------
Gross Profit Ann.
-
-
 -------
Operating Exp. Ann.
-2.5%
19.5%
99.1119.7140.4127.412994.949.220
Operating Profit Ann.
-
-
-99.1-10.5-133.8-125.2-123.8-94.9-49.2-20
-
-
6.97.41312.1-1.4-1.3-0.4
Other Exp. Ann.
-
-
 -6.5-4-21.8-5.60.4-4-224.7
PBT Ann.
-
-
-109.9-9.7-124.8-134.8-130.8-95.8-53.6-244.8
Tax Ann.
-
-
 -0.11.81.90.10--
⌄
-
-
-109.8-9.6-126.6-136.7-130.9-95.8-53.6-244.8
Diluted NI Avail to Com Stockholders Ann.
-
-
-109.8-9.6-126.6-136.7-130.9-95.8-53.6-244.8
EPS Ann.
-
-
 -0.1-1.6-2.3-2.3-3-1.3-5.9
Diluted EPS Ann.
-
-
 -0.1-1.6-2.3-2.3-3-1.3-5.9
Number Of Shares End
14.4%
15.9%
 87.385.46058.35541.8-
Total Exp. Ann.
-2.5%
19.5%
 119.7140.4127.412994.949.220
Net Income Continuing Discontinued Operations Ann.
-
-
-109.8-9.6-126.6-136.7-130.9-95.8-53.6-244.8
Normalized Income Ann.
-
-
-91.9-2.9-123.2-115.6-120.9-95.8-48.9-18.8
Interest Income Ann.
-
-
6.97.41312.7----
Interest Ann.
-
-
 -0.51.110.4
EBITDA Ann.
-
-
-86.82.6-111.5-121.2-121.3-91.1-51.8-244.5
Reconciled Cost Of Rev. Ann.
-
-
 -------
Reconciled Depr. Ann.
16%
56.4%
12.313.113.3138.43.81.40.3
Profit From Continuing Operations Ann.
-
-
-109.8-9.6-126.6-136.7-130.9-95.8-53.6-244.8
Normalized EBITDA Ann.
-
-
-68.99.4-107.1-99.8-111.3-91.1-47.1-18.6
*All financials are in USD Million and price data in USD
Total Rev. Ann.
1Y CHG
1554.5%
2Y CAGR
604.5%
3Y CAGR
175.9%
Operating Exp. Ann.
1Y CHG
-14.7%
2Y CAGR
-3.1%
3Y CAGR
-2.5%
5Y CAGR
19.5%

Century Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • NEGATIVE

    Total Shareholders Fund Century Therapeutics Inc Dec-2025 Total Shareholders Fund is $159 Million which is growth of -1.5% YoY.

  • NEGATIVE

    Total Assets Century Therapeutics Inc Dec-2025 Total Assets is $224 Million which is growth of -36.7% YoY.

Century Therapeutics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-22.8%
15.9%
223.7353.2360.7486.5437.4106.890.9
⌄
-29.4%
-21.2%
64.8191.9175.9183.841.1213.2182.8
⌄
-19.3%
-
158.9161.4184.8302.7396.2-106.4-91.9
Total Capitalization Ann.
-19.7%
-
158.9161.4184.8306.5405.1-96.8-91.9
Tangible Assets Ann.
-25.6%
-
124.7127.2184.8302.7396.2-115.8-91.9
Working Capital Ann.
-29.8%
8.5%
100.564.3159.2289.9212.566.781.1
Invested Capital Ann.
-20.2%
-
158.9161.4184.8313406.2-96.8-91.9
Tangible Book Value Ann.
-25.6%
-
124.7127.2184.8302.7396.2-115.8-91.9
Borrowings Ann.
-4.1%
15.1%
43.653.848.249.425.121.6
Net Debt Ann.
-
-
-------
Share Issued Ann.
14.4%
9.8%
87.585.860.358.55554.854.8
Number Of Shares End
14.4%
15.9%
87.385.46058.35541.8-
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
-36.7%
2Y CAGR
-21.2%
3Y CAGR
-22.8%
5Y CAGR
15.9%
Total Current Liabilities Ann.
1Y CHG
-84.4%
2Y CAGR
6.2%
3Y CAGR
-12.2%
5Y CAGR
10.8%
Total ShareHolders Funds Ann.
1Y CHG
-1.5%
2Y CAGR
-7.3%
3Y CAGR
-19.3%

Century Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • NEGATIVE

    Book Value Per Share Century Therapeutics Inc Book Value Per Share is $1 which is growth of -47.2% YoY.

  • NEUTRAL

    ROE Century Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Century Therapeutics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
RoA Ann. %
-
-
--35.46%-32.26%-28.34%-35.22%-54.21%-269.28%
ROE Ann. %
-
-
--73.14%-56.07%-37.46%-66.13%--
ROIC %
-
-
--16.5-17.1-8.6-6.4--
OPM Ann. %
-
-
-9.62%-2,030.81%-5,600.94%-2,381.82%---
Inventory Turnover Ratio Ann.
-
-
-------
Asset Turnover Ann. %
-
-
-000---
Working Capital Turnover Ann.
-
-
1.10.100
Quick Ratio Ann.
-
-
-1.59.810.614.36.327.3
Current Ratio Ann.
-
-
-1.59.910.714.66.528.1
Interest Coverage Ratio Ann.
-
-
---248.6-117.4-97.9-139.6-
LT Debt To Equity Ann.
-
-
-0.30.30.10.1--
*All financials are in USD Million and price data in USD

Century Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • POSITIVE

    Cash From Operating Activity Century Therapeutics Inc Dec-2025 Cash From Operating Activity is $-104 Million which is growth of 5.7% YoY.

  • NEGATIVE

    Net Cash Flow Century Therapeutics Inc Dec-2025 Net Cash Flow is $4 Million which is growth of -68.1% YoY.

Century Therapeutics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-
-
-103.9-110.1-88.414.1-89-41.3-16.2
-
-
107.547.561.1-13.1-298.3-22.8-19.8
-80.6%
-66.5%
0.274.6-9.727.2417.847.774.8
Cash Plus Cash Eqv. End Of Year Ann.
-9%
18.6%
6561.249.386.258.227.770.3
Net Increase In Cash Plus Cash Eqv.s Ann.
-48.7%
-
3.811.9-36.928.130.4-16.338.8
Cash Plus Cash Eqv. Begin Of Year Ann.
1.7%
6.8%
61.249.386.258.227.744.131.4
Income Tax Paid Supplemental Data Ann.
-20.6%
-
0.53.11.110.2
Interest Paid Supplemental Data Ann.
-
-
-------
Capex Ann.
-
-
-0.9-0.2-13.7-30.6-45-9.8-2.5
Issuance Of Capital Stock Ann.
-80.6%
-
0.274.60.527.2381.274.8
Issuance Of Debt Ann.
-
-
----9.7
Repayment Of Debt Ann.
-
-
--10.2----
Repurchase Of Capital Stock Ann.
-
-
-------
Free Cash Flow Ann.
-
-
-104.7-110.3-102.1-16.6-134-51.1-18.6
*All financials are in USD Million and price data in USD
Cash from Investing Act. Ann.
1Y CHG
126.3%
2Y CAGR
32.6%
Cash from Financing Act. Ann.
1Y CHG
-99.7%
3Y CAGR
-80.6%
5Y CAGR
-66.5%